Celyad licenses technology to Novartis

Belgium-based Celyad SA, which used to go by the name of Cardio3 BioSciences SA, has secured a non-exclusive licensing agreement with Novartis giving the Swiss company rights to US patents for the production of allogeneic CAR T cells.

Full text available to subscribers only. Click here for information on subscribing to MedNous.